<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04200248</url>
  </required_header>
  <id_info>
    <org_study_id>RBM 007-002</org_study_id>
    <nct_id>NCT04200248</nct_id>
  </id_info>
  <brief_title>A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration</brief_title>
  <acronym>TOFU</acronym>
  <official_title>A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of RBM-007 Monotherapy and RBM-007 in Combination With Eylea® Compared to Eylea® Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ribomic USA Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ribomic USA Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, active-controlled, double masked study assessing the safety, efficacy&#xD;
      and durability of four monthly intravitreal (IVT) injections of RBM-007 monotherapy, and four&#xD;
      monthly RBM-007 injections in combination with Eylea® dosed at every other month, compared to&#xD;
      Eylea® monotherapy dosed at every other month in approximately eighty-one subjects with&#xD;
      exudative age-related macular degeneration (AMD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RBM-007 is a novel oligonucleotide-based aptamer having potent anti-FGF2 activity and&#xD;
      anti-VEGF-expression activity&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity - continuous</measure>
    <time_frame>Week 16</time_frame>
    <description>Mean change in Best Corrected Visual Acuity from Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity - categorical</measure>
    <time_frame>Week 16</time_frame>
    <description>Proportion of patients gaining more than 15 letters as measured by Best Corrected Visual Acuity from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular thickness change</measure>
    <time_frame>Week 16</time_frame>
    <description>Change from Baseline in Central Subfield Thickness by spectral domain optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular volume change</measure>
    <time_frame>Week 16</time_frame>
    <description>Change from Baseline in macular volume by spectral domain optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis change</measure>
    <time_frame>Week 16</time_frame>
    <description>Change from Baseline in sub-retinal hyper-reflective material by spectral domain optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Ocular</measure>
    <time_frame>Week 20</time_frame>
    <description>Ocular examination (biomicroscopy and ophthalmoscopy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Systemic - Heart rate</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in heart rate (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Systemic - Blood pressure</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in systolic and diastolic blood pressure (millimeters of mercury)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Exudative Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Sham + RBM-007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sham + RBM-007 intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RBM-007 + Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RBM-007 + Aflibercept intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham + Aflibercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sham + Aflibercept intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBM-007 Injectable Solution</intervention_name>
    <description>RBM-007 Injectable Solution</description>
    <arm_group_label>RBM-007 + Aflibercept</arm_group_label>
    <arm_group_label>Sham + RBM-007</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>EYLEA® (aflibercept) Injection, for Intravitreal Use</description>
    <arm_group_label>RBM-007 + Aflibercept</arm_group_label>
    <arm_group_label>Sham + Aflibercept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Sham intravitreal injection</description>
    <arm_group_label>Sham + Aflibercept</arm_group_label>
    <arm_group_label>Sham + RBM-007</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide signed written informed consent.&#xD;
&#xD;
          2. Male or female 55 years of age or older on the date of signing the consent and able&#xD;
             and willing to comply with all treatment and study procedures.&#xD;
&#xD;
          3. Diagnosis of exudative age-related macular degeneration in the study eye, for which&#xD;
             previous standard treatment with intravitreal anti-vascular endothelial growth factor&#xD;
             agents (at least 4 injections over the past 8 months) has demonstrated incomplete&#xD;
             resolution of exudation, as assessed by spectral domain optical coherence tomography.&#xD;
&#xD;
          4. Presence of macular edema or subretinal fluid.&#xD;
&#xD;
          5. Absence of central atrophy or retinal epithelial tear in the fovea or any condition&#xD;
             preventing visual acuity improvement in the study eye.&#xD;
&#xD;
          6. Visual acuity of 78 to 24 letters (20/32 to 20/320) in the study eye.&#xD;
&#xD;
          7. Visual acuity of 24 letters (20/320) or better in the fellow eye.&#xD;
&#xD;
          8. Reasonably clear media and some fixation in the study eye to allow for good quality&#xD;
             tomography and fundus photography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ocular:&#xD;
&#xD;
               1. Use of any of the following treatments or anticipated use of any of the following&#xD;
                  treatments to the study eye:&#xD;
&#xD;
                    1. Any intravitreal treatment within 4 weeks prior to Baseline (Visit 1).&#xD;
&#xD;
                    2. Intravitreal or periocular corticosteroid, within 90 days prior to Visit 1&#xD;
                       (Day 1) and throughout the study.&#xD;
&#xD;
                    3. Fluocinolone acetonide intravitreal implant, within 12 months prior to Visit&#xD;
                       1 (Day 1) and throughout the study.&#xD;
&#xD;
                    4. Visudyne® photodynamic therapy, within 90 days prior to Visit 1 (Day 1) and&#xD;
                       throughout the study.&#xD;
&#xD;
               2. Uncontrolled or advanced glaucoma, evidenced by an intraocular pressure of &gt; 21&#xD;
                  mmHg or cup/disc ratio &gt; 0.8 while on medical therapy, or chronic hypotony (&lt; 6&#xD;
                  mmHg) in the study eye.&#xD;
&#xD;
               3. Evidence of any other ocular disease other than wet age-related macular&#xD;
                  degeneration in the study eye that may confound the outcome of the study&#xD;
&#xD;
               4. History of vitrectomy in the study eye.&#xD;
&#xD;
               5. Need for ocular surgery in the study eye during the course of the study.&#xD;
&#xD;
               6. YAG laser capsulotomy within 30 days prior to Visit 1 (Day 1) in the study eye.&#xD;
&#xD;
               7. Intraocular surgery, including lens removal or laser, within 90 days prior to&#xD;
                  Visit 1 (Day 1) in the study eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Padma Bezwada, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>RIBOMIC USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Research Institute, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants Medical Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95841</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Retina Associates</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research, LLC</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Retina, P.C.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raj K. Maturi, M.D., P.C.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute, PA</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Ophthalmology Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 8, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibrosis</keyword>
  <keyword>Edema</keyword>
  <keyword>Neovascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

